Although hypomethylating drugs promote the induction of several genes during oncogenesis, the association found between aberrant DNA methylation of TIMP3 and poor prognosis for patients with the disease suggests that the TIMP3 methylation rate could be an additional useful new prognostic biomarker of disease in AML and open the door to new therapeutic approaches by potentiating NK cell anti-leukemic potential. This evidence concerns the gene TIMP3 and acute myeloid leukemia.